Related news: Novo Nordisk’s Recombinant Coagulation Factor Ⅷ Applied for Marketing Ahead of Chiatai Tianqing!
Coagulation factor Ⅷ marketed in China includes the first generation, second generation, and third generation, wherein, Chinese pharmaceutical enterprises mainly market the first generation, and overseas pharmaceutical enterprises market the second and third generations. Roche’s Emicizumab Injection has been marketed in China since the end of last year, which attracts much attention. As a recombinant humanized bispecific monoclonal antibody, emicizumab was approved by the U.S. FDA for marketing at the end of 2017; the drug has a longer action time compared to other hemophilia drugs and requires only one subcutaneous injection every week, being the only long-acting recombinant coagulation factor Ⅷ marketed in China at present.
